Based on the provided data, the forecasted sales of diabetes medicine in Norway show a consistent upward trend from 2024 to 2028. In 2023, the sales value stood at 9.3. Year-on-year variations highlight significant growth:
- 2024: Value - 10.8 (Year-on-Year growth: 16.1%)
- 2025: Value - 12.4 (Year-on-Year growth: 14.8%)
- 2026: Value - 14.1 (Year-on-Year growth: 13.7%)
- 2027: Value - 15.8 (Year-on-Year growth: 12.1%)
- 2028: Value - 17.4 (Year-on-Year growth: 10.1%)
From 2023 to 2028, the Compound Annual Growth Rate (CAGR) stands at approximately 13.36%. This sustained growth trend suggests increasing demand for diabetes medications over the next five years.
For future trends, it is crucial to monitor the impact of population aging, advancements in diabetes treatment, potential policy changes, and public health initiatives aimed at preventing and managing diabetes. Additionally, technological innovations in diabetes care and increased prevalence of diabetes should continue driving market growth.
